美吉姆(002621.SZ):一季度預虧900萬元-1200萬元 同比轉虧
格隆匯4月14日丨美吉姆(002621.SZ)披露2022年第一季度業績預吿,預計2022年第一季度實現歸屬於上市公司股東的淨利潤為虧損900萬元-1200萬元,上年同期為盈利759.11萬元。業績變動原因系:
1、2022年第一季度國內部分地區出現點狀疫情反覆,處於相應地區的部分美吉姆早教門店階段性暫停線下授課導致營業收入下降。
2、公司自2021年11月26日暫停履行《業務託管協議》,該報吿期不再收取上述《業務託管協議》相關託管費。
3、公司於2021年12月完成出售子公司北京楷德教育諮詢有限公司100%股權,該報吿期合併範圍不再包括北京楷德教育諮詢有限公司。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.